BioPharmSignal logoBioPharmSignal

Biotech News

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

Vistagen Therapeutics, Inc. (VTGN)Vistagen Therapeutics, Inc.Partnership

Collaboration combines Vistagen’s neuroscience expertise and datasets with GATC Health’s predictive modeling capabilities to provide additional insights for protocol development and resource allocation Collaboration combines Vistagen’s neuroscience expertise and datasets with GATC Health’s predictive modeling capabilities to provide additional insights for protocol development and resource allocation

Related news

ANLAdlai Nortye Ltd.2026-10-15 11:00 EST

Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

VTGNVistagen Therapeutics, Inc.2026-08-06 12:30 EST

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

ANVSAnnovis Bio2026-09-23 12:00 EST

Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease

VTGNVistagen Therapeutics, Inc.2026-09-22 12:30 EST

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

SNYSanofi2026-10-01 05:00 EST

Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

SNYSanofi2026-09-14 13:03 EST

Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

TEVATeva Pharmaceutical Industries2026-08-28 10:17 EST

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

XERSXeris Pharmaceuticals2026-09-09 12:30 EST

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

View all latest news

Vistagen Therapeutics, Inc.

Intranasal Pherine Platform Vistagen is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal therapies that modulate nose-to-brain neurocircuitry. Its pherine candidates are designed to produce therapeutic effects without requiring systemic absorption or direct uptake into the brain, potentially reducing...

Recent company news

VTGNVistagen Therapeutics, Inc.2026-10-20 12:30 EST

Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs

VTGNVistagen Therapeutics, Inc.2026-09-24 11:00 EST

Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety Disorder

VTGNVistagen Therapeutics, Inc.2026-09-22 12:30 EST

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

VTGNVistagen Therapeutics, Inc.2026-09-10 12:30 EST

Vistagen to Present at Psych Congress 2026

VTGNVistagen Therapeutics, Inc.2026-08-14 12:32 EST

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

Stock data

Close
0.19 USD
Market cap
22.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States